We have performed expression profiling to define the molecular changes in dysferlinopathy using a novel dedicated microarray platform made with 3 0 -end skeletal muscle cDNAs. Eight dysferlinopathy patients, defined by western blot, immunohistochemistry and mutation analysis, were investigated with this technology. In a first experiment RNAs from different limb-girdle muscular dystrophy type 2B patients were pooled and compared with normal muscle RNA to characterize the general transcription pattern of this muscular disorder. Then the expression profiles of patients with different clinical traits were independently obtained and hierarchical clustering was applied to discover patient-specific gene variations. MHC class I genes and genes involved in protein biosynthesis were up-regulated in relation to muscle histopathological features. Conversely, the expression of genes codifying the sarcomeric proteins titin, nebulin and telethonin was down-regulated. Neither calpain-3 nor caveolin, a sarcolemmal protein interacting with dysferlin, was consistently reduced. There was a major up-regulation of proteins interacting with calcium, namely S100 calcium-binding proteins and sarcolipin, a sarcoplasmic calcium regulator.
INTRODUCTION
The limb-girdle muscular dystrophy type 2B (LGMD2B) and the distal muscular dystrophy of Miyoshi (MM), are caused by mutations in the human dysferlin gene (1, 2) . Originally, these myopathies were regarded as two distinctive disorders despite the fact that they were independently assigned to the same chromosomal region 2p13 (3) (4) (5) (6) . The reason for this distinction was based on the different muscles that are involved in the initial clinical manifestation of these myopathies. LGMD2B tends to affect early the proximal muscles of the arms whereas the Miyoshi myopathy affects the posterior muscles of the leg (especially the gastrocnemius and soleus). The dysferlin gene product is a membrane-associated protein that is a member of a recently defined class of homologous protein called 'ferlins'. Other members of this group are the Caenorhabditis elegans spermatogenesis factor fer-1 (7), the human FER-1 like protein (8) , otoferlin (9) and myoferlin (10) . Dysferlin immunolocalizes to the sarcolemma similarly to dystrophin, but it does not associate with the dystrophin-glycoprotein complex. The function of the dysferlin protein and the damage and regression of muscle fibre in its absence are still under investigation. A functional clue may be the presence of six hydrophilic domains called C2. These motifs can bind calcium and mediate the interaction of proteins with cellular membranes (11) . For other proteins these domains have been correlated to events of signal transduction and membrane trafficking. A direct interaction of dysferlin with the protein caveolin-3 has been discovered recently (12) . This is a transmembrane protein that is localized in the caveolae of muscle fibres that are invaginations of the sarcolemma. Given these features and the homology data, a role has been postulated for the dysferlin protein in the membrane fusion or repair (13) .
Molecular diagnosis of dysferlinopathy is now available and a number of patients have been diagnosed and analysed. The dysferlin gene is composed of 55 exons spanning a large genomic region of roughly 237 kb (14) (NCBI LocusLink ID 8291) and the types of gene alterations that have been characterized so far include missense mutations as well as deletions and insertions. LGMD2B patients are characterized by a wide inter-and intrafamiliar variation in clinical phenotypes, but since these variations have not been correlated with specific gene mutations, the influence of other 'modulator' genes has been assumed (15) . The onset of clinical signs occurs in the second decade, although dystrophic muscle pathological changes and increased creative kinase (CK) level might be evident earlier. Dysferlin protein appears early during development as it can be detected in embryonic tissues at 5 weeks of age (16) . Since this is the time when the limbs form regional differentiation, it has been suggested that a lack or reduction of this protein at this critical point of development might cause the pattern and the extent of muscle damage that grows into dysferlinopathy in adult life (16) . The late onset of dysferlinopathy involving primarily the proximal (LGMD2B) or distal (MM) musculature could then be due to the effect of a network of other modulator genes.
We decided to use the cDNA microarray technology to study the gene expression signature in LGMD2B. DNA chips and microarrays are potent tools to determine the genetic background underlying both genetic and non-genetic human pathologies (17, 18) . A growing number of studies, especially in the field of cancer, are demonstrating that gene expression profiling can be used to categorize patients affected by the same clinical class of tumour into different sub-classes that are characterized by variations in the expression levels of a group of cancer-distinctive genes (19, 20) . In the field of skeletal muscle, DNA arrays have been used to study general problems such as the muscle specificity of collections of genes (21) or the difference in gene expression of muscles in different physiological and pathological conditions such as aging and energy restriction (22) , thyroid hormone regulation (23) or atrophy (24, 25) . In a recent work, Hoffman and collaborators (26) used the Affimetrix DNA chip platform to determine the gene expression profile of Duchenne muscular dystrophy (DMD) using RNA from a pool of biopsies of DMD patients. No such study has been done so far on the dysferlinopathies.
To contribute to the understanding of the muscle pathogenesis of LGMD2B, we have analysed the gene expression profiles of a series of patients affected by this muscular disorder. These patients were characterized at the clinical level by a series of biochemical and morphological parameters and for most of them the mutation type had been determined. Pools of RNAs of LGMD2B patients were compared with normal muscle RNA to establish the common pattern of over-and under-expressed genes in this disorder. Then muscle RNA of single affected individuals was used to try to correlate the individual expression signature to some particular clinical trait. In the Discussion we consider the significance of groups of functionally related transcripts, as well as single ones, whose expression level was shown to be altered.
On-line Supplementary Information containing complete sets of expression data and lists or profiles of altered muscle transcripts found in our experiments is available at http:// muscle.cribi.unipd.it/microarrays/dysferlinopathies/
RESULTS

Patients and clinical data
The present study involved eight Italian patients (three females and five males), including two pairs of siblings (1, 5 and 7, 8) , one of whom was born to consanguineous parents (Table 1) . Seven patients presented with distal Miyoshi myopathy and one had LGMD phenotype; they had disease onset between 11 and 33 years of age (mean 19.5) and underwent muscle biopsy between 19 and 37 years of age (mean 29.5). The time lapse between the age of the onset and the muscle biopsy (disease duration) ranged from 0-24 years (mean 10). The clinical course or disease progression was intermediate in four cases and rapid in the remaining four, causing the loss of independent ambulation after the age of 35 in the second group.
Analysis of dysferlin protein and gene
We used western blot analysis with specific antibodies to determine the dysferlin protein content among the patients in this study. Dysferlin protein was completely absent in four cases, barely detectable in two cases (<5% of control) and markedly reduced in two cases (10-20% of control; Table 1 and Fig. 1A ).
Dysferlin gene mutations have been identified in five cases (Table 1) : one pair of siblings were compound heterozygotes for two missense mutations in exon 20 and 45; another pair of siblings born to consanguineous parents, were homozygous for a nonsense mutation in exon 32. In another sporadic patient only one mutant allele was identified with a missense mutation in exon 38. None of these four mutations has been reported previously in other dysferlinopathy patients.
Muscle pathology and immunohistochemical data
A series of immuno-and histochemical tests were applied to patient specimens to classify them according to our muscle pathological severity score ( Table 2) . The results can be summarized as follows. One case had mild myopathy, one had moderate dystrophy, five had active dystrophy and one had advanced-stage dystrophy. The two latter categories are characterized by an increased fibre size variability and fibrofatty replacement and a case with advanced stage dystrophy showed many lobulated fibres (Table 2) . We did not find any correlation between the severity of pathological picture and the disease duration. The highest rates of degeneration (>1% of total fibres) and regeneration (>10% of fetal myosin positive fibres) were present in muscle biopsies showing active or moderate dystrophy (Table 2 and Fig. 1B ). An increased inflammatory response resulting in a moderate or marked increase in MHC-1 and/or macrophage reaction was observed in almost all muscle biopsies. Increased MHC-1 reaction was associated with the presence of macrophages (Table 2) and was also localized in the cytoplasm of regenerating fibres (Fig. 1B) . Caveolin-3 showed normal expression and cellular localization by both immunohistochemical and immunoblot analysis (Fig. 1) .
The human muscle array
Our group has produced a muscle-specific microarray that, at the moment comprised 2688 different cDNA clones, collected within a project for systematic sequencing of skeletal muscle-specific cDNA libraries. These libraries were produced using a strategy that allows the selection of the 3 0 -end region of the mRNAs (27) . The use of the 3 0 -end of cDNA clones ensures the detection of as many unique transcripts as possible, since this is the less conserved part of the genes. We have previously demonstrated that the 3 0 -end of a transcript is very useful for discriminating between different members of the same gene family using hybridization (28) . This is especially important for muscle, where a number of significant genes can be translated into many different protein isoforms. The specificity of the 3 0 -end cDNA clones was tested by examining the crosshybridization of the muscle ESTs of the actin multigene family. We have demonstrated that the 3 0 -end fragment of the skeletal muscle isoform of alpha actin was not able to hybridize to the gamma actin, or to the cardiac isoform of alpha actin. In fact, these three genes share a high degree of identity ($86%) at the nucleotide level in the coding region, whereas their 3 0 -UTRs are clearly divergent. The strategy for library construction was also designed to obtain 3 0 -cDNAs with very uniform size (300-500 bp). This feature ensures that all the cDNA clones of the collection can be PCR-amplified and spotted with similar efficiency and it guarantees, moreover, the production of arrays with uniform hybridization characteristics. We have diminished the redundancy in our muscle microarray, by eliminating multiple cDNA clones belonging to the same transcript, unless their sequences were aligning with different regions of the corresponding gene. Special care has also been taken to avoid 3 0 -ESTs containing repeated sequences. In many cases they have been replaced with a 3 0 -fragment of the same transcript but taken specifically from a region immediately upstream of the repeat.
To establish a threshold level for the identification of differentially expressed genes with our array platform, we performed a series of experiments in which the muscle arrays were hybridized with aliquots of the same RNA that was labelled with two different fluorochromes (Cy3 and Cy5). The statistical analysis of these data shows that 99% of the distribution of the logarithmic transformation of the spot intensity ratios lies within AE0.8 (data not shown, but available in the Supplementary Information). Furthermore all the hybridization experiments show that the variance is constant along the entire range of spot intensity values. Therefore in our analysis the genes that exceed these values are considered as differentially expressed. In the fifth column is reported a clinical severity score, properly modified for dysferlinopathy by the Gardner-Medwin and Walton scale, that was used to classify our patients. The features of each category of this scale are as follows: grade 0, preclinical, hyperCKemia, all activities normal; grade 1, normal gait, inability to run freely, myalgia, atrophy; grade 2, difficulty in walking on tiptoes, defect of posture/gait; grade 3, muscle weakness, stepping gait, climbing stairs with banister; grade 4, presence of Gower's sign; grade 5, unable to rise from floor; grade 6, unable to climb stairs; grade 7, unable to rise from a chair; grade 8, unable to walk without assistance; grade 9, unable to eat, drink or sit without assistance. In the seventh column the disease progression was considered as 'intermediate' when during a 5 year period there was a two-grade change; 'rapid' when during a 5 year period there was a three or more-grade change. In the last column we report the percentage of dysferlin protein from western blot analysis. Expression profiling of LGMD2B using the patient's RNA pools
To determine the general picture of gene expression alteration in LGMD2B, we mixed equal amounts of total RNAs from seven different patients selected because they had received biopsies on the same muscle (quadriceps femoralis, see Table 2 ). The pooled RNAs were applied in competitive hybridization on the human muscle array with pooled RNAs prepared from quadriceps femoralis of healthy individuals. This experiment aimed at reducing the genetic polymorphic variation in expression patterns between different individuals and at decreasing the experimental variability.
Polymorphic variations in expression profiles should be normalized by this approach, while expression alterations correlated with the primary biochemical defect should be retained (26) . We performed two replicas of the same experiment with the RNA pool labelled alternatively with Cy3 or Cy5 fluorochromes. After spot normalization, the average value for each spot replica in each array was calculated (see the Materials and Methods section for details). Figure 2A shows the distribution of the calculated expression levels for the muscle cDNA collection. Transcripts that were calculated to have log 2 ratio intensity between dystrophic and normal muscles greater than 0.8 or lower than À0.8 were recognized as overexpressed and underexpressed, respectively. A total of 69 transcripts, represented by 78 cDNA clones, fell into these categories (3% of the genes represented in the muscle array). Of these, 50 (72% of the differentially expressed genes) were overexpressed and 19 (28% of the differentially expressed genes) underexpressed. In Table 3 these genes are listed according to their biological function (www.geneontology.org). A companion table, with genes ordered instead by expression value, is reported in the Supplementary Information. In Figure 2B the altered expression pattern in pooled patient RNA is summarized by grouping the differentially expressed genes according to their function. The biological processes that are mostly affected in this muscular dystrophy appear to be the metabolism of calcium (S100 calcium binding protein A6 being the gene with the highest value of up-regulation), immune response and muscle contraction. In particular, we found a general underexpression of genes that code for the giant structural proteins of the sarcomere (titin and nebulin) and an overexpression of genes directly related to inflammation (e.g. MHC I).
Validation of the expression profiling by RT-PCR
Quantitative RT-PCR using the SYBR-Green method (29) was undertaken to quantify the level of expression of some muscle transcripts in dystrophinopathy mRNA in order to validate our novel 3 0 -cDNA array platform. To this aim, we have selected a set of nine genes, distributed along the entire range of variation of gene expression, found in the pooled RNA experiments described before. Of these, four were underexpressed (dysferlin, very-long-chain acyl-CoA dehydrogenase, titin and telethonin/T-Cap), two overexpressed (S100 calcium binding protein A6/calcyclin and S100 calcium binding protein A4) and three not differentially expressed (fatty acid binding protein 3, caveolin 3 and glyceraldehyde-3-phosphate dehydrogenase). The housekeeping gene ubiquitin A-52 was used as an internal control. As can be seen from Figure 3 , we found quite a good correlation for all the tested transcripts between the expression values obtained with the quantitative RT-PCR and those obtained with the cDNA platform. Titin was underexpressed in both systems but with a more negative value in microarray analysis. The correlation coefficient of RT-PCR/microarray values for all the tested transcripts is 0.5, but reaches 0.65 if the titin value is excluded. These data confirm the usefulness of our specific cDNA collection and microarray platform for expression studies of muscle tissues. All the biopsies considered in our experiments were obtained from quadriceps femoralis except for patient 7 for whom biopsy was obtained from deltoid (first column). To evaluate muscle fibre type composition, we used the anti-slow myosin antibody as a marker of type 1 fibres. General inspection of serial sections routinely stained as described in the Materials and Methods was used to evaluate the overall muscle morphology and the following pathological changes were measured or recorded: range of fibre size variability (fourth column), endomysial and perimysial connective tissue proliferation, fatty replacement (fifth column), fibre splitting, presence of lobulated fibres (on NADH-TR stain) (sixth column). The extent of each pathological change was judged by visual inspection and graded by comparison with control as follows: absent or normal (À), slightly increased (þ), moderately increased (þþ), severely increased (þþþ). Muscle fibre degeneration was expressed as the percentage of fibres calculated by the addition of opaque fibres, hyaline fibres and those undergoing phagocytosis. Muscle fibre regeneration was expressed as the percentage of fibres showing positive labelling with anti-fetal myosin, laminin A and vimentin antibodies used as markers of regeneration. On the basis of the above parameters, the degree of dystrophic process and muscle histopathology severity was classified in four different categories: mild myopathic picture moderate dystrophic process active dystrophic process and advanced-stage dystrophic process (last column).
Expression profiling of single LGMD2B patients
In a second series of experiments, the muscle arrays were used to compare RNA purified from muscle biopsies of five single LGMD2B patients with pooled RNA from correspondent muscle of normal donors, in independent competitive hybridization. RNAs from patients 1, 2, 4 and 5 were compared to normal quadriceps RNA, while RNA of patient 7 was compared with normal deltoid RNA. These five patients are characterized by different clinical severity score and different disease progression. The experiment design and the statistical analysis of the expression data were as described before. The idea was that the analysis of expression profiles of single patients would allow the identification either of putative genes specific to some particular pathological trait, or of a pattern of altered transcripts that is typical of patient's pathological response. Expression profiles of the five LGMD2B patients underwent a two-way hierarchical analysis and the result is presented in Figure 4A . Initially, as a general analysis, we have identified clusters of genes that show either a common under-or overexpression, respectively, among all five affected individuals. In our database (http://muscle.cribi.unipd.it/), which contains all the information about the muscle transcripts present in our array, these are classified according to different biological processes, as obtained from LocusLink (www.ncbi.nlm.nih.gov/LocusLink/). Therefore we have analysed the expression levels of the various gene functional classes only considering the expression behaviour of the entire group. Complete results and detailed gene tables are available in the Supplementary Information. As expected, we found a general underexpression of the striated muscle-contraction regulation genes, an overexpression of immune response and complement activation genes. Moreover, there was an overexpression of genes involved in myogenesis, intracellular protein trafficking, lipid metabolism and proteolysis. Finally we found a large group of genes belonging to the 'protein biosynthesis' class that includes nearly all the ribosomal proteins that appear generally overexpressed.
When we compared the genes differentially expressed in microarray experiments with pooled biopsy RNAs, with the genes found differentially expressed in all the five patient RNAs tested independently, we found that the two lists do not completely overlap. In order to thoroughly explore this aspect, in each of the five patients, we checked the expression levels of two groups of the transcripts that were found to be down-or upregulated in the pooled RNA experiments. The profiles of these genes are shown in Figure 4B and C, respectively. As can be seen, the expression levels of some of these genes have slightly discordant values in patients 4 and 7. This means that the use of pooled RNA may not be sufficient to study the expression profile of a particular muscle transcript in this muscular disorder. To give a more general view of the patient's specific gene expression variation, we have also added in Table 3 , together with the values of deregulated genes found with pool experiments, the values obtained in the single patient profiles.
The hierarchical clustering shown in Figure 4A clearly identifies two main groups: patients 4 and 7 seem to be different according to their global expression levels from patients 1, 2 and 5. Similar results have been obtained with different algorithms. Even though the use of clinical data and the gene expression profiling should be considered as two independent approaches for patient classification, it is interesting that the second cluster in the tree includes three patients whose biopsies were characterized by a common pathology severity score (Table 2) . It is also interesting that patients 4 and 7 received biopsy in different muscles (quadriceps femoralis and deltoid, respectively), but all the analyses still cluster them together. However, subtle variation between their profiles could be due to the different muscle source. 
DISCUSSION
Gene expression in LGMD2B
Our study on gene expression in the dysferlinopathies has been structured into two parts. In a first set of experiments we compared RNA pools from the same muscle of different patients with normal muscles, in order to identify the general picture of gene expression in LGMD2B. A second series of experiments was designed to obtain the specific expression profiles of single LGMD2B patients. These individuals were extensively characterized using a variety of clinical parameters as well as morphological biochemical and immunological tests, and presented different grades of severity of pathological manifestation. Differentially expressed genes found in pool experiments did not completely correspond to those found as differentially expressed in all patients, when analysed separately (Table 3 and Fig. 4 ). This phenomenon is due to the influence that single patients have on gene expression levels in pool experiments (Table 3) , and also to genes that are specifically altered only in subgroups or even in one single affected individual (Fig. 4 and Supplementary Information) .
The hierarchical clustering shows that the expression profiles of the five patients belong to two distinct groups. This result has been confirmed by applying different algorithms to this dataset. From this analysis we obtained the genes that are either up-or down-regulated in the group composed of patients 1, 2 and 5, who present the same rating of clinically severe dystrophy (active, see Table 2 ). The complete list of these genes is reported in the Supplementary Information. In some cases, the genes belonging to these two categories (such as lectin galactoside-binding soluble 3 binding protein, cathepsin D, zinc finger protein 106, BTG family member 2, ATPase Na þ / K þ transporting beta 1 polypeptide and some still unknown genes) are so strongly deregulated that they appear differentially expressed even when RNA pools are used. Others are instead detected only when one examines the single-patient profiles. In patients 1, 2 and 5, differentially expressed genes belonging to the protein biosynthesis class (ribosomal proteins) and to the class of muscle development (such as Myf 6, see below) are probably related to a higher muscle regeneration process. In this list of differentially expressed genes we also found some transcripts whose products are involved in signalling processes such as, for example, ZASP/chyper (30) . This protein interacts with calsarcins, a family of sarcomeric proteins that play a central role in a network of proteins involved in the structure of the Z-disc of muscle sarcomere (31) . Calsarcins also interact with calcineurin, an important molecule involved in signal transduction in striated muscle (32) . We speculate that some of these transcripts could be related in some extent to the more severe clinical trait described for the muscles of these three patients. However, their functional role has to be carefully investigated. In this perspective it might also be of some interest to further investigate the role of transcripts whose functions are still unknown. Atrogin for example, an ubiquitin ligase that has an important role in muscle atrophy, was discovered initially as an unknown transcript up-regulated in muscle tissues that became atrophic from different causes (24, 25) .
In the following paragraphs we discuss more deeply a series of metabolic processes and a correlated group of transcripts that appear to be impaired in LGMD2B.
Inflammation
As demonstrated by our morphological and immunohistochemical analyses, the LGMD2B patients show a mild degree of muscle damage and fibre degeneration, accompanied by inflammation. This is reflected by our microarray experiments that show a general up-regulation of genes involved in immune response and complement activation. In this context, an important surface molecule that appears differentially upregulated is the major histocompatibility complex (MHC) class I that accompanies the expression of many inborn or acquired neuromuscular diseases. MHC class I expression is up-regulated both in inflammatory myopathies and in Duchenne dystrophy. In dysferlinopathies, contradictory results have been reported: Mc Nally et al. (33) found that MHC class I expression was not up-regulated in the muscle of four dysferlinopathy patients who carried a particular splicing mutation; Gallardo et al. (34) did not demonstrate increased MHC class I molecules in dysferlinopathies, whilst in our laboratory this feature has been observed in some cases (35) . In the natural model of the dysferlin-deficient SJL/L mice, MHC class I expression was up-regulated but did not determine the In the last column we report the percentage of ESTs corresponding to that transcript out of the total number of ESTs produced by our systematic sequencing project of muscle cDNAs; 0.0034% corresponds to a transcript identified by a singleton EST. The strategy used for library construction and sequencing allows a good correlation between EST frequency in our libraries and actual transcript abundance in muscle mRNA population (27, 52) . Anonymous sequence refers to a cDNA clone that so far has not found significant identity with any sequence in public databases. Patients are clearly divided in two groups by this analysis; one of these contains three patients with a similar pathology severity score assigned to their muscle biopsies (Table 2) . To underscore the variation of gene expression among different individuals, we have enlarged two clusters that contain most of the genes that were found respectively down-regulated (B) or up regulated (C) in the experiment with pooled patient RNAs. Note that the three titin spots correspond to ESTs that align with different regions of the giant titin transcript and might correspond to different isoforms of the protein.
appearance of the myopathy (36) . In fact, myopathological features were similar in SJL/L mice where MHC class I expression is impaired because of a target mutation in the b2-microglobulin gene.
Regeneration
Regeneration of muscle fibre was detected in the LGMD2B patients analysed in the present study by immunohistochemical tests using antibodies against fetal myosin, vimentin and laminin (Fig. 1B) . The microarray data confirmed an overexpression of vimentin and laminin and also gave some other clues for the regeneration processes that are implicated in this disorder. An analysis performed on genes involved in protein biosynthesis reveals a general up-regulation of this class of genes. Moreover, in the three patients characterized by a more rapid disease progression we found an up-regulation of the myogenic factors 6 (Myf6) and thrombospondin 4. On the contrary, we did not find an increased expression of MyoD, contrary to the conclusions reached in other works on mdx mouse, where a clear overexpression of both MyoD and Myf6 factors was demonstrated, albeit only weak for the second (37) .
Thrombospondins are a family of proteins involved in cell proliferation, regeneration, adhesion and migration (38, 39) and an increased expression of thrombospondin-4 was found also in Duchenne muscular dystrophy patients using DNA chip analysis (26) .
Sarcomeric proteins
The expression of the genes that codify for the principal components of the contractile machinery (actins, myosins) of the muscle sarcomere seems not to be generally affected in LGMD2B, with the exception of the myosin heavy polypeptide 7. On the contrary, the mRNAs for the giant sarcomeric proteins titin and nebulin (Table 3 ) and the small Zline protein telethonin (see Supplemental Information, table of under-expressed genes in three LGMD2B patients) are all reduced in LGMD2B. Titin acts as a molecular rule for the correct assembly of protein components of the muscle sarcomere. Titin and telethonin are linked also because they interact through the two immunoglobulin-like domains of titin that are located in the Z-line, and because telethonin is phosphorylated by titin at a particular moment in myofibrillogenesis (40) . A central role for these three proteins together with alpha-actin and alpha-actinin has been recognized in the maturation and assembly of I-Z-I bodies, which are the precursor structures of the mature Z-bands of sarcomere (41) . As previously reported, Ca 2þ alteration due to membrane damage leads to an altered regeneration pathway (26) . This altered regeneration could therefore determine a reduction of some Z-line proteins in the limb girdle muscular dystrophy resulting in a loss of fibre functionality.
Calcium metabolism
In LGMD2B, like in other muscle dystrophies, the primary genetic defect causes a general membrane instability that leads to an altered uptake of calcium ions into the muscle fibres. This increase of Ca 2þ concentration probably influences the expression of various signalling molecules whose transcription is sensible to the concentration of this cation. In this context we found an up-regulation of various S100 calcium-binding proteins such as S100A1, S100A4, S100A6 (calcyclin) and S100A11. This class of proteins is implicated in various intracellular and extracellular regulatory activities (for a review see 42). It appears particularly interesting to notice that S100 A1 can influence the functionality of the rhyanodine receptor by increasing by several fold the probability of this channel molecule keeping an open configuration (43) . This event would lead to an additional increase in the concentration of cytosolic calcium, with further consequences for muscle gene expression and functionality. As pointed out by studies on mouse mdx muscles, an increased amount of calcium produces other general effects such as an increased protein degradation (44) . Our microarrays data substantiate a general up-regulation of genes involved in proteolysis (e.g. cathepsin). As in mdx muscles, there is not a severe loss of functional proteins (45) because LGMD2B expression profiles also show a general upregulation of genes involved in protein biosynthesis and this probably compensates for the increased proteolysis.
Dysferlin and muscle proteins interacting with it
While western blotting tests show a reduction or the absence of dysferlin protein in most of the patients, the microarray data show a reduction of dysferlin mRNA for only three (1, 2 and 5; see Supplementary Information) of the five patients analysed. This could be due to the different types of mutations of the gene that affects the translation efficiency of the mRNA or the stability of the protein. It should be noted, however, that the algorithms for the analysis of microarray data do not have the capacity to consistently measure low differences of expression of transcripts that are expressed per se (like dysferlin in the muscle fibre) at a low level. It is difficult to say to what extent our expression data can be used for inferring some information on the still unclear function of dysferlin. It was proposed (13) that dysferlin might be important for membrane fusion and repair in the mature myotubes. Since dystrophic muscle is more susceptible to damage compared with normal muscle, this may lead to an increased expression of the membrane repair machinery. The membrane damage determines an increased calcium influx in the cell and alters the calcium-based signal transduction pathways. Nevertheless we have only found a small increase in proteins of the intracellular protein traffic category. It should be pointed out however, that our expression studies have been performed on muscles where the dystrophic traits have reached their completion and therefore one can expect that secondary alterations in gene expression patterns have been added to the original circuit directly influenced by the reduction of dysferlin. Probably the correct strategy to use the microarray analysis as a tool to clarify the function of a gene should be to perform a time-point analysis during the evolution of dystrophy, from the stage in which the defective gene is initially expressed to the final stage of the pathology. In this respect, animal models of the LGMD2B such as the SJL-Dysf mouse (46) should be of great help. In the skeletal muscle, dysferlin was demonstrated to interact with the protein caveolin-3 by co-immunoprecipitation experi-ments (12) . Caveolin-3 is a membrane protein that has an important role for the formation of caveolae from the sarcolemma by acting as a scaffold for the lipids and proteins that constitute these structures (47) . Mutation in this gene causes type 1C dominant limb girdle muscular dystrophy (48) and in biopsies of patients suffering this disorder the immunofluorescence test has demonstrated a concomitant reduction of dysferlin (12) . Despite this interaction, we found no consistent reduction of caveolin-3, both at transcript and protein level in the LGMD2B patients examined in this study. Our data are consistent with previous immunofluorescence analysis on LGMD2B cases (12) . It was suggested as an explanation to these apparently contradictory findings that dysferlin may be less tightly associated to the membrane than caveolin and this last protein could be less affected than dysferlin when the interactive partner is absent or reduced (12) . The calcium-activated, muscle-specific protease calpain-3 also has been suggested as a possible interactor of dysferlin, given that in eight out of 16 LGMD2B patients there was a reduction of calpain-3 expression (49). Our expression data did not show a reduction of calpain-3 transcript.
In this paper we present an initial study on gene expression profiles of muscle tissues affected by limb girdle muscular dystrophy type 2B of different severity. From the comparison between gene expression data and histological, biochemical and quantitative RT-PCR results, we can confidently assert the consistency of our microarray results. Of course, a clearer picture of the expression pattern in LGMD2B will be reached by adding to this dataset more profiles obtained from other patients with different clinical traits and gene mutations and perhaps using biopsies from muscles of different body regions. This investigation will allow not only specific disease patterns to be defined, but also specific molecular pathways and biological processes to be related to them, thus explaining specific pathological features of this genetic neuromuscular disorder.
MATERIALS AND METHODS
Patient selection, clinical data and muscle biopsies
Patients included in the present study were selected by the following criteria: weakness in distal or proximal muscle; high CK; muscle biopsy with dystrophic features; deficiency of dysferlin protein associated with normal dystrophin, sarcoglycan and calpain-3, as detected by western blot. As LGMD phenotype we classified patients with initial predominant weakness in proximal muscle of lower extremities; as MM phenotype we classified patients with atrophy and weakness in the posterior compartment of distal lower extremities. Dysferlin gene mutations confirmed the diagnosis in five patients. Out of eight patients, four were pairs of siblings. One pair of affected patients were born to consanguineous parents. A clinical severity score, properly modified for dysferlinopathy by the Gardner-Medwin and Walton scale, was used to classify our patients. The features of each category of this scale are as follows: grade 0, preclinical, hyperCKemia, all activities normal; grade 1, normal gait, inability to run freely, myalgia, atrophy; grade 2, difficulty walking on tiptoes, defect of posture/gait; grade 3, muscle weakness, stepping gait, climbing stairs with banister; grade 4, presence of Gower's sign; grade 5, unable to rise from floor; grade 6, unable to climb stairs; grade 7, unable to rise from a chair; grade 8, unable to walk without assistance; grade 9, unable to eat, drink or sit without assistance. The disease progression was considered 'intermediate' when during a 5 year period there was a two grade change; and 'rapid' when during a 5 year period there was a three or more grade change.
At the time of diagnosis, after obtaining written informed consent from the patient, open muscle biopsy was obtained under local anaesthesia from muscles in the lower (vastus lateralis of quadriceps femoris) or upper (deltoid) limbs. Muscle specimens were flash frozen by immersion in isopentane pre-chilled in liquid N 2 , and stored at À80 C until processed. Muscle biopsies from subjects in whom a muscle disease was excluded by both clinical and histopathological criteria were used as controls. For quadriceps femoralis we used biopsies from three female and two male donors ranging between 9 and 54 years of age. For the deltoid muscle we used biopsies from three male and seven female donors ranging between 13 and 57 years of age.
Muscle morphology
Serial sections of frozen biopsies (10 mm thick) were routinely stained with haematoxylin-eosin, Gomori trichrome, PAS, Oil Red-O, and with preincubations at pH 4.3 and 9.4 for the following enzymatic activities: NADH-tetrazolium reductase (NADH-TR); succinate dehydrogenase (SDH); cytochrome oxidase (COX); acid phosphatase; and adenosine triphosphatase (ATP-ase). General inspection of routinely stained sections was used to evaluate the overall muscle morphology. The following pathological changes were measured or recorded: range of fibre size variability, endomysial and perimysial connective tissue proliferation, fatty replacement, fibre splitting and presence of lobulated fibres (on NADH-TR stain). The extent of each pathological change was judged by visual inspection of the same observer and graded by comparison with control as follows: absent or normal (À); slightly increased (þ); moderately increased (þþ); or severely increased (þþþ). Muscle fibre degeneration was expressed as the percentage of fibres calculated by the addition of opaque fibres, hyaline fibres and those undergoing phagocytosis. The total number of fibres per section (on average 1500 fibres) was counted on ATPase stained sections and used to calculate the percentage of fibres immunolabelled with different antibodies. Additional serial muscle sections (6 mm thick) were used for immunohistochemical labelling and processed separately. Muscle fibre regeneration was expressed as the percentage of fibres showing positive labelling with anti-fetal myosin, laminin A and vimentin antibodies used as markers of regeneration. On the basis of the above parameters, the degree of dystrophic process and muscle histopathology severity was classified in four different categories: mild myopathic picture; moderate dystrophic process; active dystrophic process; and advanced-stage dystrophic process.
Antibodies
A panel of different monoclonal antibodies was used. To evaluate muscle fibre type composition, we used the anti-slow myosin antibody (Monosan, Uden, The Netherlands) as a marker of type 1 fibres. To study membrane proteins we used anti-dysferlin (Hamlet, Novocastra, Newcastle-upon-Tyne, UK), and anti-caveolin-3 (C38320, Transduction Laboratories, Lexington, KY, USA) antibodies. To evaluate muscle fibre regeneration we used three different markers: antifetal-type myosin (neonatal myosin MHCn); anti-vimentin (Monosan); and anti-laminin-A (Chemicon, Temecula, CA, USA). To investigate inflammatory and cellular response we used antibodies against macrophages (clone EBM11, Dako, Carpinteria, CA, USA), against CD4 helper/inducer T lymphocytes (clone MT310, Dako), anti-CD8 cytotoxic/ suppressor T lymphocytes (clone DK25, Dako), and anti MHC class I molecules (W6/32 Dako).
Immunohistochemical analysis
Biopsy serial sections were transferred onto gelatine-coated slides, air-dried for 30 min, blocked for 15 min with 5% goat serum in PBS and incubated for 1 h with appropriate monoclonal primary antibody. All antibodies were diluted in 1% bovine serum albumin (BSA) in PBS and used at 1 : 100 concentrations, except for anti-laminin-A (1:2000 dilution). After washes in 1% BSA in PBS, the primary antibody reaction was revealed by a 30 min incubation with a cyanine-3 conjugated anti-mouse Ig antibody (Caltag, Burlingame CA, USA) diluted 1 : 100. Sections were examined with a ZEISS Axioskop epifluorescence photomicroscope. The number of muscle fibres showing positive reactions for slow-type myosin, fetal-type myosin, vimentin and laminin-A was expressed as the percentage on the total fibres in each section. The extent of immunolabelling to macrophages, MHC class 1, helper and cytotoxic T lymphocytes was graded by comparison with normal control as follows: absent or normal (À); slight increase (þ); moderate increase (þþ); or marked or severe increase (þþþ). The localization of inflammatory cellular exudates was also recorded.
Immunoblot analysis
Two parallel sets of cryostat sections of patient and control muscle biopsies were obtained. One set of sections was used for non-collagen protein determination by Bradford's method. The second set of sections, whose protein concentration was previously measured, was dissolved in loading buffer (0.05 M DTT, 0.1 M EDTA, 0.125 M Tris, 4% SDS, 0.05% bromophenol blue, pH 8.0), boiled for 3 min and centrifuged. A volume of supernatant corresponding to 80 mg of proteins was loaded in 1.5 mm thick 3.5-12% polyacrylamide gradient gels. Broad-range molecular weight markers (Bio-Rad) were used as standards. Proteins were resolved by overnight SDSelectrophoresis and then electroblotted onto nitrocellulose membrane (Schleicher & Schuell, Dassel/Relliehausen, Germany) for 3 h with cooling. Post-transfer gels were stained with Coomassie blue, whereas the blots were airdried and blocked with 2.5% BSA in TTBS (0.05% Tween-20 in Tris-buffered saline) for 1 h. Primary antibody against dysferlin (Hamlet, Novocastra) was diluted 1 : 1000 in TTBS and incubated for 1 h. Immunoreactive bands were detected by sequential incubations with anti-mouse biotinylated immunoglobulins (Amersham Biosciences, Uppsala, Sweden) diluted 1 : 1000 for 1 h, followed by streptavidin-horseradish peroxidase complex (Amersham Biosciences) diluted 1 : 1000 for 1 h, and the ECL-enhanced chemiluminescence system (Amersham Biosciences). The labelled blots were exposed to X-OMAT films (Kodak), for different times (15, 30 and 45 s) . The quantity of each protein in the patients' sample was normalized to the amount of muscle tissue loaded into each lane, as determined by the skeletal myosin heavy chain (MHC) band in the post-transfer Coomassie blue-stained gels and expressed as a percentage of the normal control samples.
Microarray fabrication
The microarrays used for this work (Human Muscle Array 1.0, see http://muscle.cribi.unipd.it/microarrays/) were constructed arraying PCR-amplified cDNAs obtained from our archive of recombinant bacterial clones, on glass slides. This archive consists of 2688 different clones collected after systematic sequencing of skeletal muscle cDNA libraries that contain only the 300-500 bp, 3 0 -portions of muscle transcripts (27) .
Amplification of cDNA inserts. Bacterial clones were kept as saturated cultures in LB medium containing 20% glycerol at À80 C. At the time of microarray construction, frozen clones were scraped and inoculated in 2 ml, 96-well assay block (Costar, Milipitas, CA, USA) containing 600 ml of LB medium plus 50 mg/ml Ampicillin and grown at 37 C for 16 h. Approximately 1 ml of culture suspension was then transferred to 96-well plates (Costar) containing 50 ml of PCR mixture (67 mM Tris-HCl pH 8. C. In order to normalize the amplification results among the bacterial clones and to increase the absolute quantity of PCR products, a second round of PCR amplification was performed. A very small quantity of the first amplification reaction ($0.1 ml) was added to 100 ml of PCR mix (the same composition as above except 240 mM of each of the four dNTPs, 0.36 mM of each of the two amplification primers and 3 units of Taq DNA polymerase). The primers used here were the universal forward primer A and a reverseanchored oligo-dT primer (5 0 -GCGGCCGC(T) 18 V-3 0 ) to drastically shorten the poly-A tracts present in the cDNA inserts to be spotted. Both primers were amino-modified at their 5 0 -end to allow a more efficient DNA binding to the organo-aldehydederivatised glass surface (ArrayIt, Telechem, Sunnyvale, CA, USA). The cycling programme was as follows: 5 min initial denaturation at 95 C; five cycles of 30 s denaturation at 95 C; 30 s annealing at 45 C and 40 s extension at 72 C then 35 cycles with the same steps except for the annealing where the temperature was set to 55 C; and a final 10 min of elongation at 72 C. The PCR success rate with this protocol was very high (0.1% of double or weak bands or amplification failures).
Clean-up of PCR reactions. For an efficient binding of PCR products to the slides it is essential to remove buffer and unincorporated nucleotides. This step was performed by vacuum filtering the PCR products using 96-well filter plates (Multiscreen, Millipore, Bedford, MA, USA). The purification protocol was automated using a robotic workstation Multimek 96 (Beckman Instruments, Fullerton, CA, USA). The purified product was recovered from filters in 50 ml of Milli-Q water and transferred in a new plate. One microliter of amplification product was separated by electrophoresis on 1% agarose gel containing ethidium bromide and the quality and quantity of DNA were checked using a Chemi Doc UV transilluminator with Quantity One software (Bio-Rad, Hercules, CA, USA). PCR reactions were then desiccated in a thermocycler at 55 C for 1 h. Plates were sealed using thermowell sealers (Costar) and stored at À20 C.
Microarray printing and post-processing. PCR products were dissolved in 25 ml of 1Â Micro Spotting Solution (ArrayIt) by vigorous mixing of the 96-well plates for 4-5 h in a plate shaker and than transferred to 384-well plates using the Multimek robotic station (Beckman Instruments). The spotting process was performed using a Genpak Array 21 robotic system (Genetix, Hampshire, UK) equipped with 16 Stealth Micro Spotting Pins SMP 3B (ArrayIt) in order to obtain spots of an average diameter of 120 mm. Each amplified cDNA insert is deposited on the slide in two replicates. The spot to spot distance is settled to 225 mm to obtain a microarray with a total printed area of 18 Â 18 mm. Spotting was performed at 55% relative humidity to obtain the best spot morphology and to reduce the evaporation from the plates. After spotting the slides were placed in a box at 100% relative humidity for 5 min to improve the spot morphology, reducing the ring-shaped spots. Microarrays were then stored for 12-16 h in a desiccation chamber under vacuum and with a relative humidity lower than 30%. To remove unbound DNA, slides were rinsed twice in 0.1% SDS and once in distilled water for 2 min at room temperature. DNA was denatured by immersing the microarrays in boiling water for 3 min and immediately plunging them in ice-cold absolute ethanol for 30 s. Processed microarrays were dried by centrifugation and stored at room temperature in a sealed box for 2-3 months without reduction of hybridization performance.
RNA purification and labelling
Frozen patient biopsies were weighed and immediately homogenized for 3-5 min using an ultra-turrax-T8 blender (IKA-Werke, Staufen, Germany) in 5 vols of TRIZOL reagent (Invitrogen/Life Technologies). Total RNA was purified following the TRIZOL standard protocol. A small aliquot of RNA was then used for quantification and quality control using the RNA 6000 LabChip kit and Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). We routinely obtain a mean quantity of 0.5 mg of RNA per mg of homogenized muscle tissue. RNA was retro-transcribed and labelled using a MICROMAX TSA labelling kit (Perkin Elmer, Wellesley, MA, USA). Two mg of total RNA were used in each reaction but only half of the labelled cDNA was hybridized to the microarray.
Microarray hybridization
Microarray hybridization was carried out in a dual slide chamber (HybChamber, GeneMachines, San Carlos, CA, USA) humidified using 100 ml of 3 Â SSC. Labelled cDNA was dissolved in 20 ml of hybridization buffer, denatured at 90 C for 2 min in a thermal cycler and applied directly on the slides. Microarrays were covered with a 22 Â 22 mm coverslip and hybridized overnight at 65
C by immersion in a highprecision water bath (W28, Grant, Cambridge, UK). Posthybridization washing was performed according to the MICROMAX TSA Detection kit (Perkin Elmer). Two replicates of each experiment were done using different microarray slides in which the sample and reference RNA was labelled either with Cy3 or Cy5 fluorochromes were crossed in both combinations.
Statistical analysis of expression data
Array scanning was carried out using a GSI Lumonics LITE dual confocal laser scanner with ScanArray Microarray Analysis Software, while raw scanner images were analysed with QuantArray Analysis Software (GSI Lumonics, Ottawa, Canada). Normalization of the expression levels was performed with SNOMAD gene expression data analysis tool, a collection of algorithms directed at the normalization and standardization of DNA microarray data, available at http:// pevsnerlab.kennedykrieger.org/snomadinput.html Global mean normalization across microarray surfaces and local mean normalization across element signal intensity are the two main data transformations applied before any other statistical analysis. In single-patient experiments, the mean of the ratio intensity measures of the two replica experiments was calculated and then, after normalization, log 2 transformation was performed for each expression level. On the other hand, expression values of the two replicates of the pool experiments were considered as two separate values and each was then converted into logarithmic transformation. Principal component analysis, cluster analysis, k-means and profile similarity searching were performed with J-Express (50), a Java tool available at www.molmine.com/index_p.html.
Detection of differentially expressed genes in experiments with pooled patient RNAs
Trials of hybridization with the same RNA labelled with Cy3 and Cy5 on a microarray slide were used as internal quality controls for the detection of a consistent threshold level.
According to these experiments we adopted a threshold level for the logarithmic transformation of the ratio intensity values of 0.8. Then, we considered as differentially expressed only those genes whose replicated spots resulted in expression values below À0.8 or above þ0.8 respectively.
Cluster analysis of expression profiles of single patients
The expression matrix of single-patient experiments has 2688 rows (genes) and five columns (patient codes 1, 2, 4, 5 and 7). A two-way hierarchical cluster analysis, with Euclidean distance measure and a complete linkage method for the calculation of the distance between clusters, was performed on the whole dataset. Furthermore, k-means cluster analysis, with k ¼ 16 and Euclidean distance measure, were performed to find a particular pattern profile with specific patient order.
Validation of relative gene expression by real-time RT-PCR
We used quantitative RT-PCR to validate the results obtained from microarray experiments. A 15 mg aliquot of total RNA from each sample was used to perform three independent cDNA syntheses in a final volume of 10 ml, using oligo-dT primer and SuperScript reverse transcriptase (Gibco/ Invitrogen). A 1 ml aliquot of diluted cDNA was amplified in 25 ml PCR reactions using SYBR Green chemistry, according to the recommendations of Applied Biosystems. Gene-specific primers were designed using Primer 3 software in order to amplify fragments of 150-220 bp in length, close to the 3 0 -end of the transcript. To avoid the amplification of contaminant genomic DNA, we selected primers lying on distinct exons, separated by a long (more than 1000 bp) intron. Gel-electrophoresis and the dissociation curve were used to assess the specificity of the amplicon. PCR reactions were performed in a GeneAmp 9600 thermolcycler coupled with a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Thermal cycling conditions were as follows: 15 min denaturation at 95 C; followed by 40 cycles of 15 s denaturation at 95 C; annealing for 30 s at 63 C; and 10 s elongation at 72 C. To evaluate differences in gene expression we chose a relative quantification method based on the standard curve method as described (51) . Levels of expression were compared with an endogenous control transcript (ubiquitin a-52) that does not appear to be differentially expressed under the experimental conditions assayed in our work.
